Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...

NEW YORK – Boston Children's Hospital has granted a worldwide license for an investigational gene therapy for sickle cell disease and beta thalassemia to Caring Cross, the nonprofit announced this ...

Janux will conduct preclinical studies of the undisclosed program targeting a validated solid tumor antigen expressed across several cancer types.

The company plans to begin enrolling the trial next quarter across eight US sites to test the vaccine as a monotherapy and in combination with Keytruda.

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

The company discussed plans to leverage MRD in drug development during a call to discuss Q4 and full-year 2025 financials.

The firm will conduct a Phase I trial of its KRAS G12D inhibitor in solid tumors and a Phase II trial of its G12C inhibitor plus an ERK1/2 inhibitor in NSCLC.

In the draft guidance, the agency discusses how sponsors can leverage MRD and complete response rates as near-term efficacy measures and speed new therapies to market.

Otsuka Pharmaceutical, which licensed the antisense oligonucleotide from Ionis, has rights to commercialize it in Europe and Asia.

The proceeds may in part fund R&D of its product candidates, which include the pan-RAS molecular glue ERAS-0015 and the KRAS inhibitor ERAS-4001.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...